We are excited to be BIO-Europe in Stockholm from 4-6 November 2024!

Gildas Lavenant, VP of Business Development and Simon Keen Vice President of Cell Line Development will both be in attendance and look forward to meeting with current and future contacts to discuss how Abzena can support all your needs for Biologics and Bioconjugates.

From antibodies (mAbs) to recombinant vaccines and bioconjugates including antibody-drug conjugates (ADCs), radioconjugates, and oligonucleotides, our team appreciates the chance to share how Abzena can assist in moving your program forward faster to its next milestone.

Schedule a Meeting